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Introduction
Chronic graft-versus-host disease (cGVHD) is a primary cause 
of nonrelapse mortality after allogeneic hematopoietic stem cell 
transplantation (HSCT) (1–4). Drug therapy for cGVHD has been 
predominantly limited to steroids and calcineurin inhibitors, 
which are incompletely effective and associated with infections 
as well as long-term risks of toxicity (5). Novel therapeutics that 
pinpoint pathogenic immune subsets might control cGVHD yet 
preserve immune effector functions.
In contrast to acute GVHD, cGVHD is a relatively acellu-
lar process that has fibrosis as a dominant feature. The specific 
immune phenomena that underlie cGVHD are variable; how-
ever, recent studies show that B cells, in addition to specific CD4+ 
T cell subsets, are key mediators of cGVHD (6–8). It has been dem-
onstrated that pathogenic antibody deposition occurs in human 
cGVHD (9–12). A network of alloreactive T helper cells, including 
Th1, Th2, Th17, and T follicular helper (Tfh) cells, infiltrate tissues 
and produce a milieu of effector cytokines resulting in antibody 
deposition, tissue fibrosis, and autoimmunity (6, 8, 13–15).
Many of the cellular activation and effector functions of these 
lymphoid subsets can be molecularly tethered to Bruton’s tyrosine 
kinase (BTK) and IL-2 inducible T cell kinase (ITK) (16, 17). BTK 
and ITK are highly conserved Tec family kinases that propagate 
immune receptor-based signaling in B and T lymphocytes, respec-
tively (16). These molecules are activated upstream by SRC family 
kinases and, upon autophosphorylation, drive downstream acti-
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model, which develops bronchiolar obliterans (BO) syndrome 
and multiorgan cGVHD without skin involvement (7, 33). In this 
model, ibrutinib blocked germinal center (GC) formation and Ig 
deposition, reduced tissue fibrosis, and reversed BO-associated 
pulmonary dysfunction. Genetic studies confirmed that ITK and 
BTK are independently critical for the development of cGVHD. 
These data strongly support the clinical investigation of ibrutinib 
as a novel therapeutic strategy for the treatment of cGVHD.
Results
Therapeutic administration of ibrutinib limits the development of 
sclerodermatous lesions in a murine cGVHD model. To assess the 
efficacy of ibrutinib as a therapeutic intervention for cGVHD, 
we used the LP/J→C57BL/6 model of sclerodermatous cGVHD, 
which develops dermal lesions characterized by hair loss, redness, 
flaking, scabbing, hunched posture, and thickened skin (32). In 
this murine model, symptoms become apparent between days 20 
and 25 and peak between days 37 and 47 after HSCT. Ibrutinib or 
vehicle treatment was initiated in randomized cohorts at day 25, 
after the initial clinical signs of cGVHD (weight loss, hair loss, skin 
redness/flaking, hunched posture, or immobility) were visible in 
the majority (72%) of mice. Upon inspection at day 39 (14 days 
after starting therapy), ibrutinib-treated mice clearly lacked the 
sclerodermatous lesions, hair loss, hunched posture, and scabbing 
that were observed in both the vehicle and cyclosporine treatment 
groups (Figure 1A). The development of cGVHD in this model was 
not effectively constrained by 10 mg/kg/d cyclosporine therapy 
that is T cell immune suppressive (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI75328DS1). Histology of representative skin lesions obtained 
vation of NF-κB, MAPK, and nuclear factor of activated T cells 
(NFAT) in lymphocytes, resulting in cellular activation, release of 
soluble effector molecules, and rapid proliferation (18). Antibody 
production by B cells hinges upon the function of BTK (17). Where-
as Th1, Treg, and CD8+ effector T cells have both ITK and resting 
lymphocyte kinase (RLK, aka TXK) to drive activation, epigenetic 
evolution of Th2 and Th17 cells conserves a singular dominant 
role for ITK (19–24). This TEC-kinase profile difference provides 
an avenue to selectively target T cell subsets potentially highly rel-
evant to cGVHD. However, to date, the individual impact of BTK 
or ITK on the development of cGVHD is unknown.
Ibrutinib is a first-in-class irreversible inhibitor of BTK and 
ITK that blocks downstream immune receptor activation (25–27). 
Numerous in vitro and in vivo studies confirm the specific activ-
ity and clinical safety of ibrutinib for the treatment of specific 
TEC-kinase–dependent malignancies (28–31). Since ibrutinib 
can block the activation of B cells via BTK inhibition as well as 
specific T helper subsets that drive the development of cGVHD 
via ITK inhibition, we hypothesized that it may be ideally suited 
to the treatment of cGVHD.
To study the multifaceted effects of this inhibitor in vivo and 
interrogate the activity of both T and B cells in the development of 
multiorgan systemic cGVHD, we used 2 complementary murine 
allogeneic HSCT models representing sclerodermatous and non-
sclerodermatous cGVHD manifestations. Here, we show that 
ibrutinib treatment ameliorates the progression of cGVHD in the 
LP/J→C57BL/6 T cell–dependent murine model of scleroderma-
tous cGVHD, reducing skin lesions, hair loss, and lymphohistio-
cytic infiltration (32). Therapeutic administration of ibrutinib also 
proved effective at combating cGVHD in the C57BL/6→B10.BR 
Figure 1. Scleroderma and skin manifestations of cGVHD are alleviated by ibrutinib therapy. At day 25 after HSCT, a total of 18 mice (from 2 independent 
experiments) were randomly assigned to ibrutinib (25 mg/kg/d), 18 to vehicle, and 11 to cyclosporine (10 mg/kg/d). Sclerodermatous lesions, hair loss, 
hunched posture, and gaunt appearance are characteristic visual indicators of cGVHD in this model. (A) Representative visual analysis of 4 randomly select-
ed mice at day 39 after HSCT. (B) H&E-stained skin preparations of sclerodermatous skin lesions showing levels of dermal fibrosis, epidermal hyperplasia, 
serocellular crusting, erosion, and lymphohistiocytic infiltration, consistent with cGVHD. Original magnification, ×200. (C) Pathologic cGVHD involvement of 
the skin was independently assessed on a scale from 0 to 8 for each mouse. Cohort averages are displayed. *P < 0.05. Error bars indicate SEM.
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plasma cells, and histiocytes surrounding bronchioles and small 
caliber vessels throughout the pulmonary parenchyma and within 
the renal interstitium. Immunohistochemistry revealed B220+ 
B cell and CD3+ T cell pulmonary infiltration in addition to CD3+ 
T cell renal infiltration in both the vehicle and cyclosporine groups, 
which was not observed in ibrutinib treatment groups (Figure 3A 
and Supplemental Figure 8). Coded pathologic analysis con-
firmed that ibrutinib improved systemic cGVHD in this model 
(P = 0.0099 for lung and P = 0.0124 for kidney) (Figure 3, B and C, 
and Supplemental Figures 9 and 10).
Maximum ibrutinib therapeutic benefit in sclerodermatous cGVHD 
requires prolonged administration. To understand the sustained 
therapeutic benefits of ibrutinib and the potential consequences 
of drug withdrawal, we conducted an additional long-term thera-
peutic experiment (Figure 3D). Once again, ibrutinib significantly 
limited cGVHD progression as compared with vehicle control 
(P = 0.0019). We also found that withdrawal of therapy at day 60 
permitted clinical breakthrough cGVHD in a single mouse (1 of 6); 
however, this was not statistically significant. A similar trend was 
observed by external cGVHD scoring (Supplemental Figure 11). 
Analysis of internal cGVHD pathology within the pulmonary and 
renal tissues on day 75 suggested that continuous long-term ibru-
tinib was more effective at controlling cGVHD; notably, internal 
pathology of the lung and kidney was not curtailed in BM-only 
recipients, indicating that certain cGVHD internal pathology in 
this model persists despite the elimination of T cells from the graft 
similar to what is observed in human allo-HSCT recipients (Sup-
plemental Figure 12, A and B). Prophylactic ibrutinib treatment 
initiated pre-HSCT at day –2 and concluded at day 25 did not yield 
a significant improvement in cGVHD progression (Supplemental 
Figure 13), suggesting that ibrutinib will be most effective when T 
and B cell responses are more fully developed.
Therapeutic administration of ibrutinib ameliorates pulmonary 
fibrosis and the development of BO. cGVHD is characterized by a wide 
variety of autoimmune manifestations that are incompletely reca-
pitulated by any single in vivo animal model. Recently published 
consensus criterion from the NIH considers BO the only pathogno-
monic manifestation of lung cGVHD (35). The C57BL/6→B10.BR 
at day 60 from vehicle- or cyclosporine-treated mice confirmed 
dermal fibrosis, epidermal hyperplasia, serocellular crusting, ero-
sion, and lymphohistiocytic infiltration, which were not observed 
in skin samples from the ibrutinib-treated group (Figure 1, B and 
C, and Supplemental Figures 2 and 3).
Ibrutinib improves sclerodermatous cGVHD progression-free 
survival and diminishes clinical and histopathological evidence of 
cGVHD. To define cGVHD severity and progression in the LP/J→ 
C57BL/6 model, we used a scoring system that quantitatively 
grades cGVHD metrics including the following: body weight, pos-
ture, mobility, hair loss, skin lesions, and vitality on a scale from 
0 to 19 by a consistent and trained unbiased observer in a coded 
(blinded) manner (Supplemental Table 1 and ref. 34). Overall, 72% 
of mice (34 of 47) had active cGVHD on day 25, and the randomly 
assigned cohorts were very similar in initial (day 25) cGVHD score 
(ibrutinib = 1.5, vehicle = 1, cyclosporine = 2.9 of a possible 19). 
Using these metrics, we found that mice treated with ibrutinib sig-
nificantly reduced the overall intensity of cGVHD compared with 
vehicle treatment (P = 0.0184) (Figure 2A, Supplemental Table 1, 
and Supplemental Figure 4). Chronic GVHD progression in this 
model is defined as a greater than 2-point increase in cGVHD 
score from the initiation of therapy (Supplemental Table 1). Data 
derived from 2 independent experiments show that ibrutinib sig-
nificantly extended median time to cGVHD progression by 14 
days; moreover, 33% (6 of 18) of ibrutinib-treated mice remained 
progression free compared with 12% (2 of 18) receiving vehicle 
(P < 0.02) (Figure 2B and Supplemental Figure 5). During the 
study period, we observed 100% survival in the ibrutinib cohort 
compared with 82% and 88% survival for cyclosporine and vehicle 
groups, respectively, which was not significant (Supplemental Fig-
ure 6). Weekly evaluation of mouse body weights revealed little 
variation between groups (Supplemental Figure 7).
In addition to the externally measurable cGVHD metrics, we 
demonstrated that the LP/J→C57BL/6 model consistently devel-
ops pulmonary and renal cGVHD among other cGVHD patholo-
gies that are infrequently observed. Evaluation of H&E-stained 
sections revealed that, compared with vehicle controls, ibrutinib 
therapy reduced cGVHD-related aggregation of lymphocytes, 
Figure 2. Ibrutinib inhibits autoimmune manifestations of cGVHD. (A) Weekly blinded analysis of cGVHD external metrics including weight, posture, 
vitality, mobility, coat, and skin in all mice from 2 independent experiments (18 vehicle and 18 ibrutinib) (Supplemental Table 1). All cGVHD scores were 
corrected for individual scores at the beginning of treatment (day 25). Error bars indicate SEM. *P < 0.01. (B) Kaplan-Meier plot of cGVHD progres-
sion–free survival. Data are derived from 2 independent experiments. Progression is defined as a greater than 2-point increase in day 25 cGVHD score 
(Supplemental Table 1) *P < 0.01.
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py (Supplemental Figure 16). Day –2 to day 28 prophylactic admin-
istration of ibrutinib in this model also did not effectively combat 
cGVHD or BO (data not shown). Overall, these data indicate that 
ibrutinib therapy reduces the underlying fibrotic pathogenesis of 
BO in the C57BL/6→B10.BR cGVHD model.
Ibrutinib limits in vivo GC reactions and Ig deposition in pulmo-
nary tissues. Ibrutinib’s ability to block B cell receptor–induced 
(BCR-induced) activation of BTK is well defined; however, it 
remains unclear whether GC reactions are effectively inhibited. 
To study this, we utilized the C57BL/6→B10.BR mouse model 
in which robust GC reactions sustain pathogenic B lymphocytes 
and lead to Ig deposition within the liver and lungs and the devel-
opment of BO. Peanut agglutinin staining revealed GC reactions 
within the spleen, and ibrutinib therapy reduced the overall size, 
cellularity, and number of GC reactions compared with those of 
vehicle-treated mice with active cGVHD (P < 0.001) (Figure 5, A 
and B). On day 60 after HSCT, isolated splenocytes from chime-
ras were analyzed by flow cytometry for CD19+GL7+CD38lo GC 
model develops multiorgan system disease including BO start-
ing at day 28 after HSCT. Therapeutic administration of ibruti-
nib beginning at day 28 and continuing indefinitely curtailed the 
development of BO in vivo as measured by pulmonary resistance 
(P = 0.0090), elastance (P = 0.0019), and compliance (P = 0.0071) 
(Figure 4, A–C). Masson trichrome staining of inflated pulmonary 
tissues from 4 mice derived from 3 experiments revealed less 
peribroncheolar collagen fibrosis among ibrutinib-treated ani-
mals (Figure 4D) and a significant reduction in pulmonary fibrosis 
(P < 0.0001) (Figure 4E). We observed 100% survival in the ibru-
tinib cohort versus 95% in the vehicle group (Supplemental Figure 
14). Weekly evaluation of mouse body weight revealed little varia-
tion between groups (Supplemental Figure 15). To examine the 
sustained benefit of ibrutinib therapy, we conducted a separate set 
of experiments in which mice were withdrawn from ibrutinib on 
day 56 after transplant. Pulmonary function tests (PFTs) at day 60 
and day 90 revealed that short-term ibrutinib therapy caused an 
eventual loss of benefit, supporting the need for continued thera-
Figure 3. Ibrutinib therapy prevents autoimmune injury in a T cell–dependent model of cGVHD. (A) Representative images from H&E-, B220-, or CD3-
stained lung and kidney tissues from mice sacrificed at day 125 after HSCT from 6 mice/group. Images were taken by a trained veterinary pathologist who 
was blinded to animal cohorts. Original magnification, ×200. (B) Blinded pathologic analysis of H&E-stained lung tissues obtained from cGVHD cohorts  
(18 vehicle and 18 ibrutinib). Lymphohistiocytic infiltration was graded on a 0 to 4 scale for each animal. (C) Blinded pathologic analysis of H&E-stained 
kidney tissues obtained from cGVHD cohorts. Portal hepatitis and vasculitis were graded on a 0 to 4 scale for each animal. *P < 0.05; **P < 0.01.  
(D) Kaplan-Meier plot of cGVHD progression-free survival in an independent experiment aimed to determine sustained benefits from continued ibrutinib 
therapy. During the course of the experiment, ibrutinib was withdrawn on day 60 from animals in the Ibrutinib (day 25 to day 60) cohort. **P < 0.001.
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Chronic GVHD sustaining T cells in this model originate from 
mature lymphocytes in the donor cell graft. To recapitulate the 
effect of ITK inhibition within these cGVHD-causative T lympho-
cytes, we administered Itk–/– splenic T cells along with BM from 
WT mice to allogeneic recipients. Day 60 PFTs including resis-
tance, elastance, and compliance were uniformly and significantly 
(P = 0.0014; P = 0.0028; P = 0.0003) reduced in mice receiving 
Itk–/– versus WT splenic T cells and comparable to non-cGVHD, 
BM-only controls (Figure 6). These data reveal that T cell ITK 
activity is necessary for the development of cGVHD.
Data from both models implicates hyperreactive BTK in B 
cells isolated from both cGVHD models (Supplemental Figure 
17). To genetically confirm the role of BTK signaling in cGVHD, 
we infused XID BM along with WT splenic T cells to mimic BTK 
inhibition. PFTs conducted at day 60 after HSCT revealed that 
BTK activity was essential to the development of BO (Figure 7). 
Pulmonary resistance, elastance, and compliance were signifi-
cantly reduced in recipients of WT T cells and XID versus WT BM 
(P = 0.0025; P = 0.0025; P = 0.0496) and comparable to XID or 
WT BM-only controls.
Ibrutinib blocks T and B cell activation in samples obtained 
from patients with active cGVHD. Our data confirm that BTK and 
ITK are critical to the development of cGVHD and that ibrutinib 
works to alleviate the symptoms associated with severe cGVHD 
in murine models. To confirm that this effect is not restricted to 
mouse models, we tested the effects of ibrutinib on CD4 T and 
B cells. Ibrutinib significantly inhibited the cGVHD-induced for-
mation of GCs within the spleen (P = 0.0222) to numbers compa-
rable to those in the no cGVHD, BM only control (Figure 5C).
The functional product of alloreactive GC B cells is secreted 
Ig, which deposits within healthy tissues. In the C57BL/6→B10.BR 
cGVHD model, BO is inextricably related to the deposition of sol-
uble Ig within pulmonary tissues and the fibrotic cascade that this 
initiates. By blocking B cell reactivity, ibrutinib limited pulmonary 
deposition of Ig as quantified at day 60 after HSCT using immuno-
fluorescent microscopy (Figure 5D). Quantification of the immu-
nofluorescent signal revealed elimination of pulmonary Ig deposi-
tion after therapeutic ibrutinib treatment (P < 0.001) (Figure 5E). 
Together, these data confirm that a clinically relevant downstream 
effect of ibrutinib therapy in the setting of cGVHD is the blockade 
of Ig deposition within healthy tissues.
Genetic ablation of BTK or ITK activity in allogeneic donor cell 
engraftment confirms that both TEC kinases are required for the 
development of cGVHD. The XID mouse in which the kinase activ-
ity of BTK is genetically abrogated and the Itk–/– mouse have been 
fully characterized on the C57BL/6 genetic background (36, 37). 
Given ibrutinib’s ability to inhibit both ITK and BTK, we sought to 
examine the relative independent contributions of ITK and BTK 
to the development of cGVHD. We therefore examined pulmo-
nary function at day 60 after HSCT, as this represents a primary 
functional measurement of cGVHD-induced lung injury and 
fibrosis in the C57BL/6→B10.BR model.
Figure 4. Collagen deposition and pulmonary function are improved in a murine model of bronchiolitis obliterans. (A–C) PFTs were performed at day 
60 after transplant on anesthetized animals. Animals (n = 4/group) were artificially ventilated and (A) resistance, (B) elastance, and (C) compliance were 
measured as parameters of distress in lung function in animals receiving 5 × 106 splenocytes (S) in addition to BM. Error bars indicate SEM. (D and E) Col-
lagen deposition within pulmonary tissues was determined with a Masson trichrome staining kit; blue indicates collagen deposition. (D) Representative 
images of collagen deposition observed in each treatment cohort (n = 8). Blue staining represents Masson trichrome–stained collagen. Original magnifica-
tion, ×200. (E) Quantification of collaged deposition (n = 8) as a ratio of blue area to total area of tissue was performed with the analysis tool in Photoshop 
CS3. Representative data from 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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B cells obtained from patients with active and persistent cGVHD. 
Data revealed that after pretreatment with 1 μM ibrutinib, CD4+ T 
cells from these patients demonstrated lower surface expression 
of CD69 after ex vivo T cell receptor (TCR) stimulation using anti-
CD3 (P = 0.033) (Figure 8A). Moreover, purified B cells that were 
pretreated with 1 μM ibrutinib showed lower levels of pBTK-Y223, 
pPLCγ2-Y1217, and pERK1/2 by immunoblot analysis (Figure 8B). 
These data confirm that ibrutinib can curtail immune receptor 
activation of human B and T cells in the setting of active cGVHD.
Discussion
Chronic GVHD develops from coordinated effects of both B and 
T cells, and multiple key functions of these cells are driven by 
TEC family kinases. Here, we show that neither XID BM nor Itk–/– 
donor T cells facilitate the development of systemic cGVHD in 
mice, identifying the importance of the TEC kinases BTK and ITK 
in cGVHD and identifying these 2 enzymes as therapeutic targets 
in this disease. Therefore, because of its ability 
to simultaneously target BTK and ITK, ibru-
tinib holds specific promise for the treatment 
of cGVHD. Our studies utilize 2 distinct but 
complementary, validated murine models of 
cGVHD: one that has dominant scleroderma-
tous features and the other with a nonsclero-
dermatous, multiorgan system fibrotic disease 
with BO (32, 33). Our results indicate that ibru-
tinib targets B and T cell–driven GC responses 
and is remarkably effective in treating cGVHD. 
In the sclerodermatous model, animals receiv-
ing therapeutic ibrutinib were often indistin-
guishable from their healthy counterparts, and 
in the nonsclerodermatous cGVHD model, no 
cGVHD manifestations were evident even at 
the end of the observation period. Moreover, 
GC reaction size, cellularity, and number were 
lower in mice receiving ibrutinib, correlating to 
a partial but significant resolution of cGVHD 
symptoms. These data are consistent with pre-
clinical data in which GC reactions are key to 
cGVHD pathogenesis; for instance, clinical responses to rituximab 
(anti-CD20 mAb) have been observed, implicating B cells as etio-
pathogenic in human cGVHD (38–40). Finally, we confirmed that 
our observation could be applied to human therapy by testing ibru-
tinib’s capacity to block the molecular activation of T cells and B 
cells directly obtained from patients with active ongoing cGVHD.
Results from our genetic ablation models reveal that BM-
derived B cells depend upon BTK for GC formation. Similarly, 
Itk–/– splenocytes are unable to cause cGVHD, suggesting that 
ITK is critical for T cell support of the fibrotic cascade. While XID 
and Itk–/– mice are useful in exploring the mechanisms responsi-
ble for cGVHD generation, there are caveats. For instance, TEC 
kinase has been shown to compensate for the lack of BTK in the 
XID mouse model, and complete genetic ablation of ITK blunts 
thymic maturation of functionally mature T lymphocytes (18, 41, 
42). As a result, we can conclude that ITK and BTK are necessary 
components for the development of cGVHD; however, we cannot 
Figure 5. GC reactions and pulmonary immunoglob-
ulin deposition are reduced with administration 
of ibrutinib. (A) GCs were imaged by staining 6-μm 
spleen sections with PNA conjugated to rhodamine 
(red) and DAPI (blue). (B) GC area (GC/mm2) was 
calculated from PNA-stained immunofluorescent 
images for each animal. The average area for each 
cohort is displayed. Error bars indicate SEM.  
(C) Splenocytes were purified from transplanted 
mice on day 60, and frequency of GC B cells was 
quantified. (D) 6-μm lung sections from day 60 
transplanted mice were stained with anti-mouse 
Ig conjugated to FITC (green) and DAPI (blue) and 
(E) quantified with Adobe Photoshop CS3. Repre-
sentative data from 3 independent experiments. 
*P < 0.05; ***P < 0.001. All measurements were 
conducted on day 60 after HSCT. Scale bars: 100 μm.
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conclude that ibrutinib’s therapeutic efficacy is solely driven by 
inhibition of these 2 TEC kinases.
In the cGVHD model that has BO as an important feature, fibro-
sis occurs by day 28 after HSCT. Intriguingly, ibrutinib treatment 
beginning on day 28 after HSCT in mice with established cGVHD 
resulted in resolution of fibrosis, suggesting that treatment in the 
early phase of cGVHD can permit tissue repair and further suggest-
ing that ongoing antibody deposition in cGVHD target organs may 
be required for a persistent fibrogenic process. Notably, for patients 
with debilitating cGVHD from fibrosis, therapies include support-
ive care, high-dose steroids, rapamycin, mycophenolate, imatinib, 
extracorporal photopheresis, IL-2, and lung transplant, all with 
incomplete efficacy and potentially serious complications (43–55). 
Although conclusions from rodent cGVHD must be validated in 
patients, our studies collectively indicate that a wide spectrum of 
cGVHD patients may benefit from ibrutinib therapy.
To examine the importance of sustained therapy, we con-
ducted studies using both cGVHD models in which mice were 
withdrawn from ibrutinib therapy around day 60 after HSCT. In 
general, we observed a loss of efficacy with removal of the drug; 
however, not all metrics were statistically significant. These data 
are consistent with our molecular understanding, which would 
imply that pathogenic T cells and B cells are restrained by the 
inhibitor but not actively depleted. Overall, these data would 
direct caution in the clinical setting when attempting to taper such 
an inhibitor after relatively short time periods.
To study prophylactic efficacy, we initiated ibrutinib treatment 
2 days prior to HSCT and continued until we begin to observe 
cGVHD (approximately 28 days). Although posttransplant admin-
istration of ibrutinib effectively controlled cGVHD, we found that 
prophylactic treatment was ineffective under these conditions. 
The ideal time frame for ibrutinib administration may coincide 
with the establishment of robust T cell–driven GC reactions that 
may take up to 1 month; prophylactic treatment alone may be inef-
fective for this reason. Furthermore, unlike rituximab, ibrutinib 
does not directly kill B cells; instead, it prevents downstream BCR 
activation, arresting cells in an unstimulated state. This effect can 
be lost after withdrawal of ibrutinib. Together, our data indicate 
that ibrutinib is likely to be better for cGVHD therapy as opposed 
to prophylaxis, should preclinical studies translate into the clinic.
Our studies focus on ibrutinib’s effect on cGVHD; however, the 
effects on infectious complications and leukemic relapse remain 
unknown. Recent mouse and human studies indicate that ibrutinib 
improves immune competence with regard to infectious complica-
tions; however, this has yet to be tested in the HSCT setting (27, 30). 
Ibrutinib also has direct antileukemic effects in both B cell–derived 
tumors and acute myeloid leukemia (AML), supporting the notion 
that it may directly aid in relapse prevention (56, 57).
Overall, our complementary in vivo models demonstrate a 
clear therapeutic benefit derived from therapeutic administra-
tion of ibrutinib to reduce the prolonged autoimmune effects of 
cGVHD. In addition, our ex vivo human data suggest that these 
conclusions likely extend to the setting of human cGVHD. These 
data support the future study of this promising therapeutic agent 
in cGVHD as well as the exploration of novel strategies that target 
specific TEC kinases in the setting of allo-HSCT.
Figure 6. Development of BO is dependent on ITK expression in donor mature T cells. (A) Day 60 PFTs from mice transplanted with WT BM and low num-
bers of either WT T cells or ITK-deficient T cells. (B) Pathologic scores in lung and (C) liver of day 60 transplanted mice. n = 5 mice/group in 2 independent 
experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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Therapeutic HSCT models. The C57BL/6→B10.BR model has been 
described previously (7). In brief, B10.BR recipients conditioned with 
120 mg/kg/d i.p. cyclophosphamide (Cy) on days –3 and –2 and 8.3 Gy 
TBI (using a 137Cesium irradiator) on day –1 were engrafted with 1 × 107 
Thy1.2-depleted C57BL/6 derived BM cells with (or without) 1 × 106 
allogeneic splenocytes.
Experiments with the LP/J→C57BL/6 model were conducted 
using methods similar to those previously described (32). Briefly, 
C57BL/6 recipients were conditioned with 8.5 Gy x-ray TBI on day 0 
and were provided 1 × 107 LP/J-derived BM cells and 2 × 106 spleno-
Methods
Mice. C57BL/6 (H2b) mice were purchased from the National Can-
cer Institute or from The Jackson Laboratory. LP/J and B10.BR (H2k) 
mice were purchased from The Jackson Laboratory. The C57BL/6 XID 
mouse, in which a specific mutation abrogates BTK kinase activity, was 
obtained from The Jackson Laboratory. The C57BL/6 Itk–/– mouse was a 
gift from Leslie Berg (University of Massachusetts, Boston, Massachu-
setts, USA) (58). Both strains are maintained on the defined C57BL/6 
genetic background (36, 37). All mice were housed in a pathogen-free 
facility at The Ohio State University or The University of Minnesota.
Figure 7. Expression of BTK in donor-derived B cells is necessary for the development of BO. (A) Day 60 PFTs from mice transplanted with low levels of 
WT T cells and either WT or XID (kinase inactive BTK) BM. (B) Pathologic scores in lung and (C) liver of day 60 transplanted mice. n = 5 mice/group from 2 
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 8. Ibrutinib limits activation of T cells and B 
cells from patients with active cGVHD. (A) Primary CD4+ 
T cells were isolated from patients with active cGVHD, 
pretreated with 1 μM ibrutinib (or DMSO), and stimu-
lated using anti-CD3 for 6 hours. Graph shows the mean 
florescence intensity (MFI) for CD69 among CD4+ T cells 
for each patient. *P < 0.05. (B) B cells isolated from 
patients with cGVHD were pretreated with 1 μM ibrutinib 
and stimulated with anti-IgM for 45 minutes. Immuno-
blot analysis of BTK, ERK, and PLCγ2 was conducted. The 
densitometric quantification of activated proteins rela-
tive to total proteins is provided. Data are representative 
of 3 experiments on 3 separate patients.
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(60). For pulmonary tissues, scores indicate the number of lympho-
plasmacytic and histiocytic cellular cuffs infiltrating the surrounding 
airways or vasculature and the number of infiltrating aggregates. For 
renal H&E-stained sections, both perivascular lymphoplasmacytic 
infiltration and intratubular protein were quantified. For additional 
details, see Supplemental Methods.
Immunoblot analysis. Experiments were conducted using conven-
tional methodology previously described (61). Blotting was conducted 
using pBTK-Y223–, BTK-, pPLCγ2-Y1217–, PLCγ2-, pERK1/2-, ERK-, 
and GAPDH-specific antibodies (Cell Signaling Technologies).
Statistics. A 2-tailed Student’s t test was used for normal data at 
equal variance. Significance was defined as P < 0.05. For cGVHD scor-
ing in the LP/J→C57BL/6 model, a linear mixed effects model was 
applied to assess the trends in cGVHD scores from days 33 to 52, using 
the measurement at day 25 as a covariate to account for differences 
in the initial measurement between treatments. Chronic GVHD pro-
gression in the LP/J→C57BL/6 model was prospectively defined as a 
greater than 2-point increase in cGVHD score from the initiation of 
therapy (Supplemental Table 1).
Study approval. All animal studies were approved by the institu-
tional animal care committees at The Ohio State University and the 
University of Minnesota.
Acknowledgments
The authors gratefully acknowledge Leslie J. Berg for providing 
critical reagents as well as Jessica MacMurray for experimental 
assistance. This work was supported by grants from the NIH (P01 
AI056299, P01 CA142106, R01 HL56067, and R01 AI34495 to 
B.R. Blazar; T32 AI1007313 to R. Flynn). In addition, support was 
provided by National Cancer Institute grants (P01 CA095426, K12 
CA133250-05, and P50 CA140158 to J.C. Byrd; T32 CA009338-
33-03 to J.A. Dubovsky), as well as grants from the American Can-
cer Society (125039-PF-13-246-01-LIB to J.A. Dubovsky), the Leu-
kemia & Lymphoma Society, the American Society of Hematology, 
Mr. and Mrs. Michael Thomas, the Harry Mangurian Foundation, 
the D. Warren Brown Family Foundation, and the Jock and Bunny 
Adams Research and Education Endowment (to J.H. Antin).
Address correspondence to: Bruce R. Blazar, MMC 109, Univer-
sity of Minnesota, Minneapolis, Minnesota 55455, USA. Phone: 
612.626.2734; E-mail: blaza001@umn.edu.
cytes by tail-vein injection. Mice surviving to day 25 begin to show 
clinical and pathological changes consistent with systemic cGVHD, 
frequently involving the skin, lung, and kidneys and infrequently 
involving hepatic or salivary gland lymphohistiocytic infiltration, 
conjunctivitis, anterior uveitis, esophagitis, and corneal ulcers. In 
our hands, this specific splenocyte and irradiation dose produces a 
cGVHD phenotype, devoid of the classic gastrointestinal lesions, 
splenic atrophy, or diarrhea associated with acute GVHD (aGVHD). 
The development of cGVHD was measured in coded fashion using a 
modified version of the scoring system originally described by Cooke 
et al. (Supplemental Table 1 and ref. 34).
Therapeutic administration of ibrutinib (provided by L. Elias) 
via drinking water was conducted as previously described (27). 
Mice received a dose of 15 mg/kg/d ibrutinib in 0.4% methylcel-
lulose by i.p. injection starting at day 28 after transplant for the 
C57BL/6→B10.BR model or 25 mg/kg/d via drinking water starting 
at day 25 after transplant for the LP/J→C57BL/6 model. Drinking 
water administration daily dose was calculated previously (Supple-
mental Table 2). In the latter strain combination, a cohort of mice was 
given cyclosporine A administered i.p. in 0.2% CMC at 10 mg/kg/d 
starting at day 25 for 2 weeks followed by thrice weekly as previously 
described (59). Unless otherwise stated, ibrutinib was administered 
until the end of the study.
For both cGVHD models, the BTK pathway was found to be con-
stitutively activated, similar to what has been identified in human 
cGVHD (Supplemental Figure 17).
PFTs. PFTs were performed on anesthetized mice using whole-
body plethysmography with the Flexivent system (SCIREQ) as previ-
ously described (7, 33).
GC detection. GC detection was conducted with 6-μm spleen 
cryosections stained using rhodamine peanut agglutinin as previ-
ously described (7).
Masson trichrome staining. Cryosections (6 μM) were fixed for 
5 minutes in acetone and stained with H&E and with the Masson Tri-
chrome Staining Kit (Sigma-Aldrich) for detection of collagen depo-
sition. Collagen deposition was quantified on trichrome-stained sec-
tions as a ratio of area of blue staining to area of total staining using the 
Adobe Photoshop CS3 analysis tool.
Histopathological scoring. Coded pathologic analysis of H&E-
stained sections was performed by A. Panoskaltsis-Mortari or B.K. 
Harrington in an unbiased manner with scores ranging from 0 to 4 
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